Precigen Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 83/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precigen Inc's Score
Industry at a Glance
Industry Ranking
83 / 158
Overall Ranking
216 / 4563
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.500
Target Price
+130.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Precigen Inc Highlights
StrengthsRisks
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
Fairly Valued
The company’s latest PE is -2.93, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 222.21M shares, increasing 7.20% quarter-over-quarter.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEOSabzevari (Helen)
Websitehttps://precigen.com/
FAQs
What is the current price of Precigen Inc (PGEN)?
The current price of Precigen Inc (PGEN) is 4.160.
What is the symbol of Precigen Inc?
The ticker symbol of Precigen Inc is PGEN.
What is the 52-week high of Precigen Inc?
The 52-week high of Precigen Inc is 5.225.
What is the 52-week low of Precigen Inc?
The 52-week low of Precigen Inc is 0.692.
What is the market capitalization of Precigen Inc?
The market capitalization of Precigen Inc is 1.47B.
What is the net income of Precigen Inc?
The net income of Precigen Inc is -126.23M.
Is Precigen Inc (PGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Precigen Inc (PGEN) has an overall rating of Buy, with a price target of 8.500.
What is the Earnings Per Share (EPS TTM) of Precigen Inc (PGEN)?
The Earnings Per Share (EPS TTM) of Precigen Inc (PGEN) is -1.418.